Fresh Tracks Therapeutics, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $8.0M | $6.9M | $404,000 | $1.8M | $7.9M | $1.6M |
| Operating income | −$6.4M | −$21.5M | −$40.2M | −$21.0M | −$24.5M | −$19.6M |
| Net income | −$5.7M | −$21.1M | −$39.5M | −$20.9M | −$23.9M | −$6.3M |
| Total assets | $11.6M | $10.3M | $29.7M | $33.6M | $18.1M | $52.3M |
| Total liabilities | — | — | $4.8M | $6.5M | $10.6M | $22.1M |
| Equity | $9.9M | $7.2M | $24.9M | $27.1M | $7.6M | $48.8M |
| EPS (diluted) | $-1.06 | $-7.51 | $-22.12 | $-0.85 | $-2.48 | — |
| Shares out. | 5.9M | 119.4M | 66.9M | 9.7M | 21.8M | 21.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −79.4%
- Net margin
- −71.1%
- Return on equity
- −57.3%
- Return on assets
- −49.1%
- Return on capital (ROCE)
- −64.0%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $1.68
- Revenue growth (YoY)
- 15.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Accruals / assets
- −11.7%clean
- Piotroski F-Score
- 6/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 warning● 2 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreementMar 7, 2024
- Shareholder voteFeb 16, 2024
- Terminated a material agreement · Director / officer changeJan 3, 2024
- Shareholder vote · Regulation FD disclosureDec 27, 2023
- Delisting / listing-standard notice · Regulation FD disclosureDec 18, 2023
- Entered a material agreementDec 15, 2023
- Shareholder vote · Regulation FD disclosureDec 15, 2023
- Shareholder vote · Regulation FD disclosureDec 1, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4PRIMARY DOCUMENTJun 11, 2024
- 4PRIMARY DOCUMENTMay 31, 2024
- 4PRIMARY DOCUMENTMay 23, 2024
- 4PRIMARY DOCUMENTMay 20, 2024
- 4PRIMARY DOCUMENTMay 8, 2024
- SC 13DSCHEDULE 13DMay 8, 2024
- 4PRIMARY DOCUMENTMay 3, 2024
- 4PRIMARY DOCUMENTApr 23, 2024
- 4PRIMARY DOCUMENTApr 11, 2024
- 4PRIMARY DOCUMENTApr 5, 2024
- 4PRIMARY DOCUMENTApr 1, 2024
- 4PRIMARY DOCUMENTMar 21, 2024
- 15-12GMar 18, 2024
- 10-KMar 15, 2024
- 4PRIMARY DOCUMENTMar 13, 2024
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.